19 November 2026

International Men’s Day: Exploring the Latest Advances in Men’s Health

International Men’s Day falls on 19 November every year and is marked in around 80 countries worldwide. In the UK, Men’s Day aims to recognise the contribution that men and boys make to our society, improve men’s health and wellbeing, and prompt discussions surrounding positive masculinity, underpinned by the goal to achieve gender equality for all. The day relates to a wide range of issues affecting men, and companies and individuals across the country are encouraged to interpret the underlying theme in a way which is meaningful to them. Issues raised by International Men’s Day include the taboo surrounding men’s mental health, the exposure of young boys to harmful online content, and violence among men. You can find out more about International Men’s Day here.

The month of November is also ‘Movember’, an initiative in the UK which raises awareness and funding for men’s health, including prostate cancer and suicide prevention. Movember is now the world’s largest men’s health community.

This year at Mathys & Squire, we have chosen to mark these occasions by highlighting recent noteworthy inventions in men’s health.

Innovations in men’s health

The detection of prostate cancer

Firstly, we have seen a spike in attention towards prostate cancer and screening procedures in the news recently, thanks in part to public figures such as Jeremy Clarkson and Stephen Fry campaigning for a new national screening programme in the UK. Prostate cancer is the most common cancer among men in the UK, with 1 in 8 men diagnosed in their lifetime. The earlier the cancer is detected, the easier it is to treat.

A new scheme will give eligible men access to the ‘Stockholm3’ test (A3P Biomedical), which examines a number of different markers associated with aggressive prostate cancer. The Stockholm3 test is intended to improve screening accuracy and enable early detection, detecting cancers missed by existing tests that measure the volume of a single protein marker, prostate-specific antigen (PSA), in the blood. The PSA test fails to detect between 30-50% of all aggressive cases of prostate cancer, whilst research shows that the Stockholm3 test finds twice as many cancers requiring treatment, as well as differentiating more accurately between harmless and harmful cancers, reducing the need for invasive biopsies. The test also helps to predict the risk of men age 45-74 later developing clinically significant prostate cancer, informing when they next need to be tested.  Currently, the test is only available in the UK through private healthcare, costing hundreds of pounds, but the not-for-profit organisation Central London Healthcare are offering it at a reduced rate to around 8,000 men and free of charge to around 2,000 men who might otherwise be unable to afford it. Increased access to this innovative test could help save and improve the lives of many men who will be diagnosed with prostate cancer.

With Artificial intelligence (AI) on the rise across all industries, it should come as no surprise that AI is playing an increasingly prominent role in medical research, with potential to improve the early detection and diagnosis of diseases, including prostate cancer. The National Institute for Health and Care Excellence (NICE) has recently recommended the use of AI-powered tools to support NHS radiologists in interpreting prostate MRI scans, helping to identify anomalies and improve diagnostic accuracy.

The potential of this technology has also been previously explored at Loughborough University, where researchers led by Dr Georgina Cosma have investigated how machine learning models can analyse biomarkers found in men’s white blood cells to identify patterns associated with prostate cancer. Published in December 2021, the research demonstrated how AI could examine a wider range of biological indicators than conventional PSA testing, potentially identifying cancers that might otherwise be missed. While further clinical validation is needed before such approaches become part of routine screening, such developments highlight the potential for AI to improve prostate cancer detection, support earlier diagnosis and ultimately improve outcomes for men.

Solutions for male fertility

Secondly, scientists are beginning to investigate male fertility more closely. Research into male fertility and reproductive health is typically less well funded than female fertility and reproductive health but fertility issues are equally as likely to stem from male factors as female.

Norwich-based spinout company Virilitas Labs has recently been awarded £700,000 in grant and investor funding to develop an at-home male fertility test. The test uses lateral flow technology (like COVID tests) to analyse fertility- and reproductive health-associated biomarkers from a semen sample.  Fertility has been undergoing a notable decline in the past decades and with now around one in six couples facing fertility issues, improved access to fertility testing is likely to be welcomed.

In October, a life-changing achievement in male fertility medicine was announced by the University of Edinburgh after decades of research, demonstrating a potential solution to fertility preservation in prepubescent boys who require chemotherapy. Chemotherapy can cause permanent fertility by permanently damaging cells which produce sperm. In adults, semen can be frozen before undergoing cancer treatment, but there is no established alternative for prepubescent boys who do not yet produce semen.

Now, NHS Lothian has carried out a trial procedure in which testicular tissue, containing spermatogonial stem cells, responsible for producing sperm, was removed and frozen from a boy in 2023 before he underwent a bone marrow transplant, and transplanted back into his body this August. After eight months, doctors will extract a portion of the transplanted tissue to see whether sperm has been produced. This procedure has never taken place before in the UK and only once before in the rest of the world, and could give boys who are diagnosed with cancer as children the opportunity to become a father later in life.

The IP angle

Through our work with ground-breaking early-stage health tech companies at Mathys & Squire, we know how important it is to get your IP strategy in place as soon as possible. Founders and inventors can take crucial steps from the beginning of the innovation process to give themselves the best chance possible of obtaining patent protection for their inventions. In particular, there are a couple of issues we frequently see:

  • Disclosures: grant applications, public pitches, and collaborations can be considered disclosure events that may affect your ability to protect your intellectual property. Disclosing details before applying for IP protection can work against you and potentially even prevent you from protecting your inventions in the future. Speaking to a patent attorney early and devising an IP strategy is essential.
  • Ownership: many research funding and grant schemes have precise terms around intellectual property ownership, especially if NHS trusts or academic institutions are involved as partners or co-developers. If you take a proactive approach to IP ownership, you may be able to ensure that any terms you are subject to are founder-friendly and clearly define who owns the IP. An unclear or unfavourable chain of IP ownership is a common red flag for investors, and can be difficult and expensive to resolve later down the line.

For more information and advice on protecting innovations in men’s health, please contact us here.